Quotient Clinical expands clinical capacity
In response to increased demand for its Synthesis-to-Clinic human ADME service
Quotient Clinical has expanded its clinical facilities in Nottingham, UK as a result of increased demand for its synthesis-to-clinic human ADME service.
The firm, the clinical arm of Quotient Bioresearch, has increased bed capacity by 50% and a dedicated sample-processing laboratory for human ADME studies has been added.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded it a supplementary accreditation.
The company says the expansion reinforces its position as a leading provider of 14C-enabled drug development services including Phase 0 microdose, ivMicrotracer, and human metabolism studies.
Quotient Clinical managing director Mark Egerton said: ‘In parallel with the recent expansion of our Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of our business.
‘Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development,’ he added.
